Santé handed infertility contract

Danish company Ferring Pharmaceuticals has drafted in Santé Communications to handle PR work across its infertility portfolio.

The agency was hired on an initial one-year contract and will handle a pan-European remit that will focus on the Menopur brand.

Ferring comms manager Sharmi Albrechtsen said Santé was the first agency retained by Ferring to promote an infertility product since she joined two-and-a-half years ago, and would focus on the UK, Germany, Spain, Italy, France and Belgium.

The PR campaign will target journals such as the UK-based Human Reproduction and the US-based Fertility and Sterility, according to Albrechtsen.

Santé, for which MD Liz Shanahan oversees the account, will assist Albrechtsen at conferences such as June’s 20th annual meeting of the European Society of Human Reproduction and Embryology, where Ferring plans to host a journalists’ workshop.

Ferring continues to use Burson-Marsteller’s London office to promote bed-wetting treatment Minirin.

As well as infertility, Ferring, based in Copenhagen, specialises in gastroenterology and endocrinology.

Earlier this month, Ferring announced a deal with Novartis Pharma to acquire the worldwide manufacturing, marketing and distribution rights for Norprolac.

Norprolac is a prolactin inhibitor used for the management of hyperprolactinaemia, a disorder that suppresses ovulation by the production of excess levels of the hormone prolactin.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in